SAREPTA THERAPEUTICS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
SAREPTA THERAPEUTICS, INC. (SRPT) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $71.80 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2024-02-28
- SAREPTA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $71.80M, a 48.57% decline from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $139.60M, a 109.92% increase from fiscal 2021.
- SAREPTA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2021 was $66.50M, a 43.16% decline from fiscal 2020.
- SAREPTA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2020 was $117.00M, a 2.09% decline from fiscal 2019.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2023-12-31 | $71.80M 10-K · filed 2024-02-28 | |
| 2022-12-31 | $139.60M 10-K · filed 2024-02-28 | |
| 2021-12-31 | $66.50M 10-K · filed 2023-02-28 | |
| 2020-12-31 | $117.00M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $119.50M 10-K · filed 2021-03-01 | |
| 2018-12-31 | $164.80M 10-K · filed 2020-02-26 | |
| 2017-12-31 | -$69.50M 10-K · filed 2019-02-28 | $69.50M 10-K · filed 2018-03-01 |
| 2016-12-31 | $54.20M 10-K · filed 2018-03-01 | |
| 2015-12-31 | $54.10M 10-K · filed 2017-02-28 | |
| 2014-12-31 | $32.20M 10-K · filed 2016-02-25 | |
| 2013-12-31 | $19.40M 10-K · filed 2015-02-26 | |
| 2012-12-31 | -$2.70M 10-K · filed 2014-03-03 | |
| 2011-12-31 | $8.10M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |